Onconetix (ONCO) Net Income towards Common Stockholders (2021 - 2026)
Onconetix (ONCO) posted quarterly Net Income towards Common Stockholders of -$4.2 million for Q1 2026, up 56.62% year-over-year from -$2.7 million in Q1 2025, and down 174.34% quarter-over-quarter from $5.7 million in Q4 2025.
Onconetix (ONCO) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Onconetix (ONCO) has reported Net Income towards Common Stockholders for 6 consecutive years, with -$4.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders rose 56.62% year-over-year to -$4.2 million; the TTM figure through Mar 2026 stood at -$10.0 million (up 82.56% YoY), while the FY2025 annual figure was -$15.5 million, up 73.63% from the prior year.
- Net Income towards Common Stockholders fell to -$4.2 million in Q1 2026 per ONCO's latest filing, from $5.7 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $5.7 million in Q4 2025 and bottomed at -$29.6 million in Q4 2024.
- Historically, Net Income towards Common Stockholders has averaged -$7.6 million across 5 years, with a median of -$4.3 million in 2022.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders slumped 594.57% — and 2025, when it surged 119.13%.
- Onconetix's Net Income towards Common Stockholders stood at -$3.2 million in 2022, then plunged by 594.57% to -$22.4 million in 2023, then tumbled by 32.63% to -$29.6 million in 2024, then soared by 119.13% to $5.7 million in 2025, then sank by 174.34% to -$4.2 million in 2026.
- Business Quant data shows ONCO's Net Income towards Common Stockholders at -$4.2 million in Q1 2026, $5.7 million in Q4 2025, and -$8.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Onconetix | 1.44 Mn | -4.50 Mn | 4,303.00 | -2.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.87 Mn |
| Mar 31, 2026 | -4.21 Mn |
| Dec 31, 2025 | 5.67 Mn |
| Sep 30, 2025 | -8.78 Mn |
| Jun 30, 2025 | -2.70 Mn |
| Mar 31, 2025 | -9.72 Mn |
| Dec 31, 2024 | -29.64 Mn |
| Sep 30, 2024 | -3.83 Mn |
| Jun 30, 2024 | -14.31 Mn |
| Mar 31, 2024 | -11.12 Mn |
| Dec 31, 2023 | -22.35 Mn |
| Sep 30, 2023 | -5.35 Mn |
| Jun 30, 2023 | -6.87 Mn |
| Mar 31, 2023 | -2.85 Mn |
| Dec 31, 2022 | -3.22 Mn |
| Sep 30, 2022 | -3.87 Mn |
| Jun 30, 2022 | -4.26 Mn |
| Mar 31, 2022 | -2.17 Mn |
| Dec 31, 2021 | -1.37 Mn |
| Sep 30, 2021 | -1.28 Mn |